Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kiniksa Pharmaceuticals International (KNSA) Net Cash Flow (2021 - 2025)

Historic Net Cash Flow for Kiniksa Pharmaceuticals International (KNSA) over the last 5 years, with Q3 2025 value amounting to -$17.2 million.

  • Kiniksa Pharmaceuticals International's Net Cash Flow fell 80654.35% to -$17.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $77.5 million, marking a year-over-year increase of 47884.8%. This contributed to the annual value of $75.6 million for FY2024, which is 61234.33% up from last year.
  • Latest data reveals that Kiniksa Pharmaceuticals International reported Net Cash Flow of -$17.2 million as of Q3 2025, which was down 80654.35% from $34.9 million recorded in Q2 2025.
  • In the past 5 years, Kiniksa Pharmaceuticals International's Net Cash Flow registered a high of $86.2 million during Q4 2024, and its lowest value of -$67.7 million during Q4 2021.
  • Moreover, its 5-year median value for Net Cash Flow was $5.3 million (2023), whereas its average is $3.2 million.
  • Its Net Cash Flow has fluctuated over the past 5 years, first plummeted by 111660.36% in 2022, then soared by 97305.04% in 2024.
  • Quarter analysis of 5 years shows Kiniksa Pharmaceuticals International's Net Cash Flow stood at -$67.7 million in 2021, then rose by 21.66% to -$53.0 million in 2022, then surged by 81.39% to -$9.9 million in 2023, then surged by 973.05% to $86.2 million in 2024, then tumbled by 119.93% to -$17.2 million in 2025.
  • Its last three reported values are -$17.2 million in Q3 2025, $34.9 million for Q2 2025, and -$26.4 million during Q1 2025.